French pharmaceutical company, Sanofi, has set an ambitious goal to generate annual sales of more than 10 billion euros ($10.76 billion) by 2030. This growth will come from a combination of recently launched and future pharmaceutical products, which will complement the success of its blockbuster anti-inflammatory drug Dupixent and its vaccines.
Focus on Immunology Treatments
Sanofi plans to prioritize research and development efforts in the field of immunology treatments. The company expects to have 25 data readouts for assets at mid to late stages of development and up to 19 regulatory submissions for its pharmaceutical assets in the next two years.
Late-Stage Pipeline Assets and Recent Launches
Sanofi's sales target is supported by its late-stage pipeline assets that have potential in multiple indications, as well as recently launched drugs. Notable new drugs include Altuviiio for the treatment of hemophilia, Sarclisa for blood cancer, and Tzield for diabetes.
Promising Pipeline Assets
Sanofi identifies three pipeline assets, amlitelimab, frexalimab, and SAR441566, as having the potential to exceed EUR5 billion in annual peak sales each. Additionally, the company sees further potential for peak sales ranging from EUR2 billion to EUR5 billion for nine other innovative medicines and vaccines.
Confidence in Growth Potential
Sanofi's Chief Executive, Paul Hudson, expresses confidence in the company's current product portfolio and the strength of its pipeline. He believes that Sanofi is well-positioned to achieve sustainable growth through 2030 and beyond.
Vaccines as a Key Revenue Source
In addition to pharmaceutical products, Sanofi aims to generate over EUR10 billion in annual sales from vaccines by 2030. This includes the recently launched Beyfortus vaccine for the prevention of respiratory syncytial virus (RSV).
Dupixent Sales Outlook
Sanofi anticipates strong growth in Dupixent sales, with an annual growth rate in the double percentage digits from 2023 to 2030. This growth will be driven by expected new indications, such as chronic obstructive pulmonary disease, as well as increased adoption for its current approved uses. The company has previously stated its expectation for Dupixent sales to reach the EUR10 billion mark in 2023.